Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 2/20 | 0.37 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501252 | 0.92 | HRH2 (0.42) | HRH2HRH1PTPN1ALDH1A1CYP3A4 | |
| SCHEMBL26504882 | 0.83 | HRH2 (0.41) | HRH2HRH1PTPN1ALDH1A1USP2 | |
| SCHEMBL26501262 | 0.79 | HRH2 (0.44) | HRH2HRH1ALDH1A1CYP3A4USP2 | |
| SCHEMBL26511248 | 0.77 | HRH2 (0.41) | HRH2HRH1ITGB3ITGA2BALDH1A1 | |
| SCHEMBL20739188 | 0.73 | HRH3 (0.48) | HRH2HRH1ALDH1A1CYP3A4TSHR | |
| SCHEMBL27381769 | 0.72 | POLB (0.55) | ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL24918192 | 0.72 | HSD11B1 (0.58) | PTPN1ALDH1A1 | |
| SCHEMBL22030326 | 0.70 | HTT (0.53) | PTPN1ALDH1A1TSHRLMNA | |
| SCHEMBL25876507 | 0.70 | POLB (0.44) | PTPN1ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL25870571 | 0.70 | POLB (0.41) | PTPN1ALDH1A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | HRH2 3216/4885HRH1 2655/4885ITGB3 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.